argenx SE at JPMorgan Healthcare Conference Transcript
Welcome to the first day of the 44th JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce argenx's CEO, Tim Van Hauwermeiren. Just a few housekeeping rules, we will take questions from the room after Tim's presentation, or you can submit those into the portal.
So with that, Tim, welcome to the conference.
Thank you, Richard. Thanks for having us. It's great to be together and kicking off this fantastic week at JPMorgan. Very warm welcome, by the way, ladies and gentlemen, to the Argenx presentation. And let me kick it off with an important question each biotech entrepreneur should ask himself.
The question actually is, who would miss you if you wouldn't exist? And in our case, that question is leading us straight to our patients on VYVGART. And I couldn't be more pleased to bring Sam today to this meeting. We're going to listen to a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
